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Changes in Natural Killer Cells and
Exhausted Memory Regulatory T Cells
With Corticosteroid Therapy in Acute
Autoimmune Hepatitis
Hannah C. Jeffery,1 Manjit K. Braitch,1 Chris Bagnall,2 James Hodson,3 Louisa E. Jeffery,1 Rebecca E. Wawman,1,4
Lin Lee Wong,5 Jane Birtwistle,6 Helen Bartlett,1 Ansgar W. Lohse,7 Gideon M. Hirschﬁeld,1,8 Jessica Dyson,5 David Jones,5
Stefan G. Hubscher,1,9 Paul Klenerman,10 David H. Adams ,1,8 and Ye H. Oo1,8
Autoimmune hepatitis (AIH) is an immune-mediated liver disease currently treated by immunosuppressive medications
with signiﬁcant side effects. Thus, novel mechanistic treatments are greatly needed. We performed prospective deep
immunophenotyping of blood immune cells in patients with acute AIH before and after corticosteroid therapy. Blood
samples from 26 patients with acute AIH (United Kingdom-AIH Consortium) were phenotyped by ﬂow cytometry at
baseline and 4 months after starting corticosteroids. Pretreatment liver tissues were stained for forkhead box P3-positive
(FOXP3POS) regulatory T cells (Tregs), clusters of differentiation (CD)56POS natural killer (NK) cells, and chemokine
(C-X-C motif) ligand 10. Chemokine secretion by cultured primary hepatocyte and biliary epithelial cells was measured by
enzyme-linked immunosorbent assay. Functional coculture assays with stimulated NK cells and Tregs were performed.
CD161 ligand, lectin-like transcript-1 expression by intrahepatic immune cells was demonstrated with ﬂow cytometry. Fre-
quencies of NKbright cells declined with therapy (P < 0.001) and correlated with levels of alanine aminotransferase (P 5
0.023). The Treg:NKbright ratio was lower pretreatment, and Tregs had an activated memory phenotype with high levels
of CD39, cytotoxic T lymphocyte antigen 4, and FOXP3 but also high programmed death ligand 1, indicating exhaustion.
Coculture experiments suggested the Tregs could not efﬁciently suppress interferon-c secretion by NK cells. Both Tregs
and NK cells had high expression of liver inﬁltration and T helper 17 plasticity-associated marker CD161 (P 5 0.04). Pre-
treatment and CD161pos NK cells expressed high levels of perforin and granzyme B, consistent with an activated effector
phenotype (P < 0.05). Lectin-like transcript 1, a ligand for CD161, is expressed on intrahepatic B cells, monocytes, and
neutrophils. Conclusion: Activated effector NK cells, which correlate with biochemical measurements of hepatitis, and
exhausted memory Tregs are increased in the blood of patients with treatment-naive AIH and decline with corticosteroid
therapy. Inadequate regulation of NK cells by exhausted FOXP3pos Tregs may play a role in AIH pathogenesis and con-
tribute to liver injury. (Hepatology Communications 2018;2:421-436)
Introduction
Autoimmune hepatitis (AIH) is an immune-mediated liver disease characterized by inter-face and lobular hepatitis(1) comprising inﬁl-
trates of both effector and regulatory T lymphocytes
(Tregs).(1,2) There have been no new therapies for
AIH for more than 3 decades, and it is becoming
increasingly clear that there are limitations to the long-
term safety and efﬁcacy of the nonspeciﬁc and empiri-
cal treatment in current use.(3) Thus, there is a need for
more effective mechanistically grounded approaches to
treatment, and a better understanding of the immune
make-up of patients before they receive treatment is
Abbreviations: AIH, autoimmune hepatitis; ALT, alanine aminotransferase; CCR7, chemokine (C-C motif) receptor 7; CD, clusters of differentia-
tion; CTLA-4, cytotoxic T lymphocyte antigen 4; CXCL-10, chemokine (C-X-C motif) ligand 10; CXCR3, cysteine-X-cysteine receptor 3; EM, effec-
tor memory; FOXP3, forkhead box P3; IFNc, interferon-c; IgG, immunoglobulin G; IL, interleukin; LLT1, lectin-like transcript 1; NK, natural
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crucial for developing such novel immune cell/
pathway-targeted treatments for AIH.
One of the challenges in studying the immune status
in patients who are treatment naive is the rapid initial
response to corticosteroid treatment. This means that
most patients are started on therapy before they can be
investigated. In the vast majority of patients, this treat-
ment is with corticosteroid or immunosuppressive
therapy, which by nature alters immune activation sta-
tus. Although studies have been performed to dissect
the immune cell composition of patients with AIH on
treatment, the immune balance between regulatory and
effector cells in the treatment-naive state and during
longitudinal follow-up of patients with acute AIH on
maintenance immunosuppression is not known.
An imbalance between clusters of differentiation
(CD)4positive[pos]CD25posCD127low Tregs(4) and effector
T cells has been proposed to contribute to the immune
pathogenesis of AIH.(2,5-7) The differentiation and func-
tion of Tregs is controlled by transcription factor fork-
head box P3 (FOXP3),(8) and mutation in FOXP3 leads
to a severe multiorgan autoimmune disorder (immuno-
dysregulation polyendocrinopathy enteropathy X-linked
syndrome) in humans.(9) CD56posCD3negative[neg] natural
killer (NK) cells are a key component of the innate
immune system and are involved in human autoimmune
diseases, such as systemic lupus erythematosus(10) and
rheumatoid arthritis.(11) NK cells are abundant in the
liver.(12) The activation and expansion of NK cells occurs
in the early stages of AIH as NK cells function as a ﬁrst
response to liver injury(13) and carry out diverse functions,
including cytotoxicity, which may be directed at target
cells, and cytokines interferon-c (IFNc) and tumor
necrosis factor a (TNFa) release, which can promote the
maturation of antigen-presenting cells to drive an adap-
tive immune response.(14) Although NK cells have been
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shown to be particularly important in liver injury in viral
hepatitis,(15,16) their frequency, function, and interaction
with Tregs in the initial presentation of AIH, before cor-
ticosteroid therapy, and during longitudinal follow-up is
not known. In addition, recruitment and positioning of
immune cells from peripheral circulation to the inﬂamed
liver is also crucial for their function.(2,17)
We hypothesized that dysregulation of effector
innate NK cells and Tregs may play a role in acute
AIH and that understanding this balance may help us
to develop speciﬁc therapies and predict response to
treatment. Based on this premise, we carried out a
detailed, prospective, longitudinal immunophenotyp-
ing of immune cell subsets in patients with acute AIH
before and 4 months after corticosteroid therapy and
studied the inﬂuence of regulatory and effector lym-
phocytes on NK cells in functional assays. In addition,
we screened for the presence of recruitment and posi-
tioning signals of liver-inﬁltrated immune cells in
treatment-naive AIH livers.
Materials and Methods
ETHICS STATEMENT
Written informed consent was obtained from all
subjects under United Kingdom-AIH (UK-AIH)
ethics. Peripheral blood and liver tissues were collected
with local research ethics committee approval
(Newcastle, 14/LO/0303; Birmingham, CA/5192).
BLOOD AND LIVER TISSUE
We used 10 mL ethylene diamine tetraacetic acid-
chelated peripheral blood samples from patients diag-
nosed with AIH. AIH was diagnosed according to
international AIH scoring criteria,(18) which included
scores from serologic, virology, and histologic informa-
tion. Samples were transported overnight to the
National Institute for Health Research Biomedical
Research Unit, University of Birmingham, for next day
analysis of immune phenotype by ﬂow cytometry.
Pretreatment, parafﬁn-ﬁxed, liver biopsy sections
were obtained from 6 Birmingham patients for analysis
by immunohistochemistry. Explanted diseased liver
was obtained from patients undergoing liver transplan-
tation for liver diseases, including primary sclerosing
cholangitis, primary biliary cholangitis, alcoholic liver
disease, and non alcoholic steatohepatitis; lymphocytes,
hepatocytes, and biliary epithelial cells were isolated as
described.(19-23)
STUDY DESIGN
The UK-AIH Consortium immunophenotyping
study reported here was set up as a prospective assess-
ment comparing the changes in a set of predeﬁned
immune cell subset features for consecutive treatment-
naive patients recruited between May 2015 and Novem-
ber 2016 and evaluating these features in relation to
changes in a set of predeﬁned biochemical factors that
indicate liver function (alanine aminotransferase [ALT],
bilirubin, and immunoglobulin G [IgG]). Immune fea-
tures compared included the frequencies of nine prede-
ﬁned, innate, and adaptive immune cell subsets (CD4,
CD8, CD4CD8, and CD4-CD8-double-negative
CD31 T cells; CD1271CD251 CD4 Tregs; CD561
NK T cells (NKT); CD191 B cells; CD56 bright NK
[NKbright] and CD56 dim NK [NKdim] cells) and their
expression of four surface markers (cysteine-X-cysteine
receptor 3 [CXCR3], interleukin [IL]-6R, CD161, pro-
grammed death ligand 1 [PD1]). The initial body of
data indicated important changes in NK and Treg sub-
sets; thus, additional analyses were initiated for subse-
quent patients to also compare the effector phenotypes of
NK subsets and the frequencies and phenotypes of effec-
tor and memory populations of CD4, CD8 T cells, and
Treg populations before and after steroid therapy.
ISOLATION OF PERIPHERAL
BLOOD MONONUCLEAR CELLS
AND IMMUNE PHENOTYPING BY
MULTICOLOR FLOW
CYTOMETRY
Please see the Supporting Methods.
FLOW CYTOMETRY ANALYSIS OF
LECTIN-LIKE TRANSCRIPT-1
EXPRESSION BY LIVER-
INFILTRATING IMMUNE CELLS
Please see the Supporting Methods.
IMMUNOHISTOCHEMISTRY
STAINING OF CHEMOKINE
(C-X-C MOTIF) LIGAND-10, FOXP3,
AND CD56 IN THE HUMAN LIVER
Pretreatment AIH liver biopsies were stained with anti-
chemokine (C-X-C motif) ligand 10 (CXCL-10) (6D4;
R&D Systems) and either anti-FOXP3 (236A/E7;
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Abcam) or anti-CD56 (CD564; Leica) on the Bond Rx
system by using Bond Polymer Reﬁne 3,30-diaminobenzi-
dine tetrahydrochloride hydrate and Bond Polymer Reﬁne
red detection substrates (Novocastra).
ENZYME-LINKED
IMMUNOSORBENT ASSAY OF
CXCL-10 SECRETION BY
STIMULATED PRIMARY HUMAN
HEPATOCYTES AND BILIARY
EPITHELIAL CELLS
CXCL-10 concentrations in culture supernatants
were measured using a bead-based Bio-Plex Pro assay
(Bio-Rad) according to the manufacturer’s instructions.
NK AND T-CELL COCULTURE
ASSAYS
Please see the Supporting Methods.
CLINICAL DATA COLLECTION
ALT, bilirubin, and IgG data were collected for
each patient before and 4 months after immunosup-
pressive therapy. All patients on the study received ste-
roid therapy. There were differences in the speciﬁc
formulation of steroid given depending on the local
practice and whether the patient had cirrhosis (pred-
nisolone) or not (budesonide). Steroid dosage followed
national and international guidelines.
STATISTICAL ANALYSIS
Comparisons between baseline and 4 months were
performed using Wilcoxon tests. Changes between
baseline and 4 months were compared to the changes in
ALT, bilirubin, and IgG using Spearman’s correlation
coefﬁcients. Comparisons across cell subsets or condi-
tions of experiment were performed using Mann-
Whitney, Wilcoxon, or Friedman tests, with Dunn’s
post-hoc analysis. Analyses were performed using SPSS
22 (IBM Corp., Armonk, NY) or GraphPad Prism
software version 6 (San Diego, CA). Data were summa-
rized graphically with error bars representing mean 6
SEM. P < 0.05 was considered signiﬁcant.
Results
We studied the baseline and month 4 peripheral
immunophenotype in 26 patients (3 male, 23 female;
median age 56 years, range 44-66 years) with serologi-
cally and histologically conﬁrmed diagnosis of acute
AIH from different National Health Service hospitals
across the United Kingdom. These patients had clini-
cal markers of disease activity with presenting ALT
(369 IU/L, range 82-1,352), bilirubin (26 lmol/L,
range 10-121), and IgG (23 mg/dL, range 14-38).
The detailed clinical characterizations of the patients
reported in the study and the medications they received
are given in Supporting Table S1.
NK CELL FREQUENCIES ARE
HIGHER IN PATIENTS WITH
CORTICOSTEROID-NAIVE AIH
AND DECLINE WITH THERAPY
To investigate changes in circulating immune cells
in the 26 patients with acute AIH, we compared their
peripheral blood immune cell proﬁles presented at
diagnosis (treatment naive/baseline) and after 4
months on corticosteroid therapy. Subsets were
deﬁned by the gating strategy in Fig. 1A. Strikingly,
frequencies of NKbright cells were signiﬁcantly higher
in 25/26 patients at baseline and declined with ther-
apy (median, 2.7% versus 0.9%; P < 0.001). Within
the total lymphocyte pool, proportions of CD8 T cells
(median, 14.4% versus 9.7%; P 5 0.004; 20/26
patients), NKT (median, 0.63% versus 0.45%; P 5
0.024; 19/26 patients), and Tregs (median, 1.6% ver-
sus 1.0%; P 5 0.055; 19/26 patients) were also
reduced with therapy (Fig. 1B). B-cell frequencies
were signiﬁcantly lower at baseline (median, 23% ver-
sus 33%; P 5 0.03), with increases after therapy
observed in 80% of cases (20/25). Other cell subsets
did not change signiﬁcantly (Fig. 1A). Overall, the
relative Treg/NKbright balance increased signiﬁcantly
with therapy (Fig. 1C), and compared to control
patients with hemochromatosis, the Treg/NKbright
ratio was signiﬁcantly reduced in treatment-naive
patients (P < 0.0001). This was not only due to lower
NKbright frequencies in hemochromatosis but also due
to higher Treg frequencies in controls compared to
patients with AIH (Supporting Fig. S2). Further-
more, there was a signiﬁcant correlation between the
changes in ALT and frequencies of NKbright cells
from baseline to 4-month follow-up (P 5 0.02) (Fig.
1D; Supporting Table S2). None of the other effector
populations (CD8 and NKT) that declined with ther-
apy altered signiﬁcantly in their balance with Tregs
(Supporting Fig. S3) or correlated with biochemical
markers of disease activity (Supporting Table S2).
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FIG. 1. Peripheral blood immune cell frequencies in patients with AIH before and after 4 months immunosuppression therapy.
(A) Gating strategy for deﬁnition of immune cell subsets, including CD4, CD8, CD4-CD8- (double-negative) T cells; CD4pos
CD25posCD127neg regulatory T cells; CD56pos T cells; NKT; CD191 B cells; CD56bright NK cells (NKbright), and CD56dim NK cells
(NKdim). (B) Cell subset frequencies as a proportion of total lymphocytes at baseline and after 4 months. Wilcoxon test, *P < 0.05,
**P < 0.01, ***P < 0.0001. Red dots indicate patients with high starting B cell frequency that declined dramatically with therapy. (C)
Ratio of Tregs to NKbright cells in steroid-naive, 4-month follow-up, and hemochromatosis (control) blood. Wilcoxon test, **P <
0.01; Mann-Whitney U test, *P < 0.05, ****P < 0.0001. Error bars are means 6 SEM. (D) Scatterplot and Spearman’s correlation
coefﬁcient for the association between changes in ALT levels and NKbright cell frequencies between baseline and 4 months. Trend line
calculated by linear regression is shown.
                                                                                                                                      
                                                                                                                                      
FIG. 2. Frequencies of memory/naive CD8, CD4, and Treg subsets in treatment-naive AIH before and after 4 months immunosup-
pression. (A) T-cell memory and naive subsets were identiﬁed based on expression of CD45RA and CCR7. Representative
ﬂuorescence-activated cell sorting plots illustrating the gating strategy are shown. (B) Frequencies before treatment. Friedman test
with Dunn’s post-hoc analysis, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (C) Frequencies of EM CD4, CD8, and Tregs
before and after 4 months immunosuppression. Wilcoxon test, *P < 0.05. Abbreviations: CM, central memory; TEMRA, terminally
differentiated tissue resident effector memory RA-positive.
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Corticosteroid therapy was thus associated with a
change in the immune balance toward a higher pro-
portion of Tregs over NKbright cells.
BOTH REGULATORY MEMORY
AND EFFECTOR MEMORY T-
CELL FREQUENCIES ARE
SIGNIFICANTLY HIGHER IN THE
CIRCULATION IN TREATMENT-
NAIVE PATIENTS WITH AIH AND
DECLINE AFTER THERAPY
We additionally explored whether T cells had been
exposed to antigen by assessing the memory/naive status
of the cells in a subgroup of the cohort (n5 12 treatment
naive; n 5 9 follow-up). We deﬁned memory and naive
CD4, CD8, and Treg populations by their expression of
CD45RA and chemokine (C-C motif) receptor 7
(CCR7)(24,25) as central memory (CD45RAnegCCR7pos),
effector memory (EM; CD45RAnegCCR7neg), naive
(CD45RAposCCR7pos), and tissue-resident terminally
differentiated effector memory RApos (TEMRA;
CD45RAposCCR7neg) (Fig. 2A). Within the CD4 and
CD8 populations in the treatment-naive state, naive CD4
T-cell and TEMRA CD8 T-cell subsets predominated
(Fig. 2B). In contrast, the EMTreg subset was the signiﬁ-
cantly predominant Treg population (Fig. 2B). In all T-
cell classes, we observed signiﬁcantly higher frequencies of
EM cells at baseline compared to follow-up (Fig. 2C).
MEMORY Tregs EXPRESS
SUPPRESSIVE FUNCTIONAL
MARKERS BUT ALSO PRESENT
AN EXHAUSTED PHENOTYPE IN
PATIENTS WITH
CORTICOSTEROID-NAIVE AIH
FOXP3 transcription factor controls Treg func-
tion.(8) Cytotoxic T lymphocyte antigen 4 (CTLA-
4) leads to transendocytosis of CD80/86 on den-
dritic cells to down-regulate antigen presentation,(26)
and CD39 generates immunosuppressive adeno-
sine.(27) Memory Tregs had signiﬁcantly higher
expression of these markers compared to other Treg
groups in the treatment-naive patients (Fig. 3A,D;
Supporting Fig. S4).
When we assessed the proportions of the Treg frac-
tions deﬁned by CD25 and CD45RA expression in
treatment-naive patients, we observed a predominance
of fraction III (Fig. 3 B,C). However, fraction II had
the highest level of Treg functional markers FOXP3,
CTLA-4, and CD39 (Fig. 3D; Supporting Fig. S3).
Previous studies suggested that fraction III Tregs
express CD161 and have a high propensity for differ-
entiation toward a T helper (Th)17 phenotype.(25,28,29)
We found that CD161 expression on Tregs (median
frequency, 12.9% versus 11.0%; P 5 0.042; median
ﬂuorescence intensity, 118 versus 100; P 5 0.037) was
signiﬁcantly higher before treatment (Fig. 3E). The
frequency of CD161pos Tregs was also higher before
therapy compared to the 4-month follow-up (Support-
ing Fig. S5). Memory Tregs and fraction III Tregs had
the highest expression of CD161 (Supporting Fig.
S6A). In addition, PD1, a marker of lymphocyte
exhaustion, was reduced on Tregs after 4 months of
immunosuppressive therapy (median, 46 versus 40;
P 5 0.027) (Fig. 3F).
NK CELL CD161 EXPRESSION
LEVELS ARE SIGNIFICANTLY
HIGHER IN THE TREATMENT-
NAIVE STATE, AND CD161pos NK
CELLS ARE CHARACTERIZED BY
HIGH EXPRESSION OF
GRANZYME B AND PERFORIN
With the exception of CD19pos B cells, all immune
subsets contained CD161pos cells (Supporting Fig.
S5). The level of CD161 expression on NKdim cells
(median ﬂuorescence intensity, 274 versus 217; P <
0.001) was signiﬁcantly higher before treatment com-
pared with after 4 months corticosteroid (Fig. 4A;
Supporting Fig. S5). We characterized the expression
of functional cytolytic molecules by NK subsets sub-
divided according to CD161 expression and observed
the highest frequencies of cytotoxic factors granzyme
B and perforin in the CD161pos NK populations.
CD161pos NKdim cells had signiﬁcantly greater
expression of both perforin and granzyme B on a cell
by cell basis than NKbright cells (Fig. 4B,C; Support-
ing Fig. S6B).
Because we detected high frequencies of CD161pos
cells, we explored the expression of the CD161 ligand
lectin-like transcript 1 (LLT1), by liver-inﬁltrating
immune cells. We analyzed its expression by cells iso-
lated from explanted autoimmune or inﬂammatory dis-
eased liver tissue by ﬂow cytometry (Fig. 4D) and
detected LLT1 on T and B cells, monocytes, and neu-
trophils (Fig. 4E).
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FIG. 3. Treg phenotype in acute AIH. (A) Expression of Treg functional proteins FOXP3, CTLA-4, and CD39 by memory/naive
Treg subsets deﬁned as in Fig. 2 by CD45RA and CCR7 expression. (B) Gating strategy for Treg fractions based on CD45RA and
CD25 expression. (C) Frequencies of fractions in AIH pretreatment. In A and C, tests were Friedman with Dunn’s post-hoc analysis,
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) Representative ﬂow cytometry overlays showing expression of Treg func-
tional proteins FOXP3, CTLA-4, and CD39 by the total Treg population; fractions I, II, and III Tregs; and the memory and naive
Treg subsets. (E) CD161 (MFI) and (F) PD1 (frequency) expression by total Tregs at baseline and after 4 months therapy. Wilcoxon
test, *P < 0.05. Abbreviations: CM, central memory; MFI, median ﬂuorescence intensity; TEMRA, terminally differentiated tissue
resident effector memory RA-positive.
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FIG. 4. Characterization of CD161-expressing NK cells and CD161 ligand LLT1 in AIH. (A) CD161 expression on NKdim cells at
baseline and after 4 months therapy. Wilcoxon test, *P < 0.05. (B) Representative ﬂow cytometry plots and overlays showing gran-
zyme B and perforin expression by CD161pos and CD161neg NK cell populations pretreatment. (C) Summary data on granzyme B
and perforin expression by CD161pos populations of NKbright and NKdim cells pretreatment; **P < 0.01. (D) Flow cytometry gating
strategy for identiﬁcation of immune cell subsets, including neutrophils, monocytes, T cells, and B cells, among isolated liver-
inﬁltrating immune cells and representative staining of LLT1 versus isotype control on these populations. (E) Summary data on
LLT1 expression by liver-inﬁltrating immune cells isolated from primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver
disease, and nonalcoholic steatohepatitis explanted livers. Abbreviation: MFI, median ﬂuorescence intensity.
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Tregs AND NK CELLS IN
TREATMENT-NAIVE AIH SHOW
HIGH EXPRESSION OF CXCR3,
AND CXCR3 LIGAND CXCL-10
DERIVES FROM INFLAMED LIVER
HEPATOCYTES AND BILIARY
CELLS
CXCR3 was expressed by all subsets of immune
cells, but expression levels varied (Supporting Fig. S7).
CXCR3pos Treg frequencies in the total Treg
population were signiﬁcantly higher in the treatment-
naive state than at follow-up (P < 0.001) (Fig. 5A).
The expression of CXCR3 was highest in the memory
compared to naive Treg populations (P < 0.05) (Sup-
porting Fig. S8). We have previously reported a role
for CXCR3 in lymphocyte homing to the liver,(2,17,30)
but to conﬁrm its potential involvement in the patho-
genesis of acute AIH, we stained pretreatment liver
biopsies for the CXCR3-binding chemokine CXCL-
10. CXCL-10 was detected on bile ducts in the portal
tracts and was closely associated with inﬁltrating
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FIG. 5. CXCL-10 distribu-
tion in treatment-naive AIH
livers colocalizes with CD561
NK cells and FOXP31
Tregs. (A) CXCR3 expression
by total Tregs at baseline and
after 4 months therapy. Wil-
coxon test, *P < 0.05. (B,C)
Dual staining of CXCL-10
and either (B) CD56 or (C)
FOXP3 on liver biopsy sec-
tions taken at diagnosis of
AIH (CXCL-10, brown
staining; FOXP31Tregs,
CD561NK cells, red stain-
ing). (D) CXCL-10 concen-
trations in culture
supernatants prepared from
untreated and IFNc 1
TNFa-treated hepatocytes and
biliary epithelial cells. Data
are mean 6 SEM. Abbrevia-
tion: BEC, biliary epithelial
cell.
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FOXP3pos Treg cells (Fig. 5B) and CD56pos NK cells
(Fig. 5C). Furthermore, we demonstrated that
CXCL-10 was secreted by human hepatocytes and bil-
iary epithelial cells in response to inﬂammatory cyto-
kines in vitro (Fig. 5D).
REGULATORY T-CELL CONTROL
OF NK CELLS
To investigate whether the signiﬁcant increase in
the ratio of NK cells to Tregs could have functional
implications in AIH pathogenesis, we tested whether
activated NK cell effector responses could be con-
trolled by Tregs in vitro. CD3negCD56pos NK cells
activated overnight with cytokines IL-12 and IL-15
secreted high levels of IFNc but expressed little
TNFa or CD107a (Fig. 6A). In agreement with the
idea that there is inadequate Treg control over NK in
the AIH disease process, we observed a very clear
trend of suppression of NK activity by Tregs (P 5
0.0625); marked suppression by Tregs occurred in
ﬁve out of the six experiments performed. This was in
contrast to the effects of coculture of NK cells with
activated non-Treg effectors, which led instead to sig-
niﬁcantly elevated IFNc expression by NK (P 5
0.0312) (Fig. 6B).
IMMUNOLOGICAL MARKERS
AND PERIPHERAL BLOOD LIVER
BIOCHEMISTRY AND IgG LEVEL
Finally, we explored whether any phenotypes
examined in this study could deﬁne patients with
treatment-naive AIH who are nonresponders to corti-
costeroid therapy. We deﬁned subjects as nonres-
ponders based on their having 1.5 3 upper limit of
normal (ULN) values for ALT, 1.5 3 ULN values
for bilirubin, and 1.5 3 ULN values for IgG at 4
months. Only 2 patients fulﬁlled these criteria, so any
interpretation is limited; however, these patients were
characterized by high levels of CXCR3 on their
NKbright cells and CD4 T cells (Fig. 6C,D) and lower
expression of the exhaustion marker PD1 on CD4 T
cells (Fig. 6E).
Discussion
Type-1 AIH is an immune-mediated liver disease
that usually responds to immunosuppression. Because
patients are promptly treated with corticosteroids, it is
difﬁcult to study patients in the treatment-naive state
before immunosuppression is started. Our study is one
of the ﬁrst to characterize in detail the changes in
immune cell composition before and after treatment in
patients with AIH. The study was not designed to
report the alterations in total cell numbers with therapy
but rather to discuss the inﬂuence of therapy on the
ratios of the different innate and adaptive immune sub-
sets and to describe the changes in their individual
phenotypes; as such, this study offers important insight
into the subsets whose relative precedence may be key
to AIH pathogenesis and thus crucial to target in
future targeted therapies.
The two main ﬁndings of this study are a signiﬁcant
elevation of activated effector CD56bright NK cells in
the blood prior to therapy and a concomitant increase
in regulatory T cells. In the healthy state, NK cells
constitute 5%-15% of peripheral blood cells and are
abundant in the liver.(31) NK cells have been impli-
cated in liver injury(32) and in the pathogenesis of auto-
immune diseases, such as systemic lupus
erythematosus and diabetes.(33,34) They provide an
early host defense to infection or injury and have the
ability to kill other cells rapidly by cytolysis through
their release of cytolytic mediators without prior stimu-
lation.(35) We observed a signiﬁcant increase in
CD56bright NK cells in untreated patients with AIH
(25/26 cases) that fell after 4 months of immunosup-
pressive treatment. CD56bright cells are found in the
liver but under normal circumstances are present at low
frequencies in the blood. They are critical for local
innate immune responses and are increased at sites of
inﬂammation in autoimmune diseases.(36) We also
observed a higher frequency of NKdim cells (up to
40%) in treatment-naive patients. It is possible that in
treatment-naive AIH, NK cells enter the peripheral
circulation from the liver, but perhaps more likely, they
are released into the blood from lymphoid tissues
where they are found at high frequencies. In parallel to
an increase in NK cell frequency, we also observed an
increased Treg frequency in the circulation of patients
with treatment-naive AIH. Tregs are crucial to main-
tain peripheral immune tolerance and control effector
immune cells.(37,38) The increase in the Treg popula-
tion may thus be an attempt to suppress immune acti-
vation stimulated by the causative autoantigen in acute
AIH. Although both NKbright and Treg cell frequen-
cies were increased in treatment-naive patients, the
Treg versus NKbright cell ratio was reduced, suggesting
a skewing of the immune balance toward the effector
arm in the treatment-naive state. Importantly, Tregs
HEPATOLOGY COMMUNICATIONS, Vol. 2, No. 4, 2018 JEFFERY ET AL.
431
were weak suppressors of NK cell production of
inﬂammatory cytokines; thus, the data suggest that loss
of NK cell regulation could underlie hepatic damage in
AIH. In support of this conclusion, the NKbright cell
frequency correlated with levels of ALT in treatment-
naive patients.
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FIG. 6. Regulation of NK cell function by activated regulatory and nonregulatory T cells. (A,B) NK cells, Tregs, and non-Tregs
were isolated from peripheral blood. NK cell degranulation (CD107a), IFNc, and TNFa production, with overnight IL-12 (20 ng/
mL) 1 IL-15 (20 ng/mL) stimulation monitored by ﬂow cytometry in the presence or absence of activated Tregs or non-Tregs. (A)
Representative and summary data on NK degranulation and cytokine production with stimulation. (B) IFNc production by NK cells
cultured overnight alone or 1:1 with either Tregs or non-Tregs under IL-12 (20 ng/mL) 1 IL-15 (20 ng/mL) stimulation. (C-E)
Expression of immune cell surface markers in responders and nonresponders after 4 months corticosteroid treatment. CXCR3 MFI
on (C) NKbright cells and (D) CD4 T cells. (E) PD1 MFI on CD4 T cells. Abbreviation: MFI, median ﬂuorescence intensity.
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A previous in vivo study(39) in diabetes suggested
that Tregs suppress NK function by depleting IL-2,
which is critical for NK cell survival and optimal func-
tion, from the local environment. Although in the pre-
sent study the suppression of NK cell production of
inﬂammatory cytokines did not reach signiﬁcance,
there was a clear indication that Tregs offer a level of
regulation over activated NK cells in the normal state.
It is possible that in the treatment-naive state of AIH,
Tregs may be too exhausted, a conclusion supported by
their elevated PD1 expression pretreatment, or too
infrequent to effectively control NK cell activity. Over-
all, the data suggest that loss of NK cell regulation
involving inadequate Treg-mediated control could
underlie hepatic damage in AIH. In support of this
conclusion, the NKbright cell frequency correlated with
levels of ALT in treatment-naive patients.
The changes in peripheral blood described in this
study are informative, although it is likely that the
most important responses pathologically are those that
occur within the liver. Our data suggest that the
expanded peripheral populations we have seen have the
potential to be recruited to the inﬂamed liver because
they express high levels of the chemokine receptor
CXCR3, which facilitates the recruitment of effector
and regulatory T cells to the inﬂamed human liver(2,30)
through interactions with its ligand CXCL-10.(2,17,30)
We detected both CXCR3pos Tregs and NK cells
residing close to CXCL-10-expressing bile ducts in
liver biopsies from patients with acute AIH.
We examined the Treg subset in treatment-naive
patients in more detail and found that these cells were
predominantly CD45RAneg memory, which suggests
that they have been exposed to antigen. Speciﬁcally,
Tregs and also CD4 and CD8 cells were predomi-
nantly of an EM phenotype before exposure to immu-
nosuppression, and this proportion declined
signiﬁcantly in all subsets after therapy. Thus, it is
likely that the EM component of Tregs is reﬂective of
extensive efforts to suppress antigen-primed effector T
cells in the liver.(40) Future studies into the T-cell
receptor repertoire of both CD4 and Tregs in
treatment-naive AIH would be of interest to deter-
mine whether these cells are clonally expanded subsets
that respond to the same antigen. In addition, Treg
functional markers FOXP3, CD39, and CTLA-4
were highest on the memory population, suggesting
that these are suppressive memory Tregs. However,
these cells also expressed high levels of PD1, which has
been associated with T-cell exhaustion, suggesting that
these cells may not be fully functional. This could
explain in part why immune-mediated liver injury pro-
gresses in spite of increased Treg frequencies.
Treg cells in peripheral blood can be divided into
three fractions,(25) with fraction III Tregs characterized
by the expression of CD161,(28,29) which has been
described as a potentially plastic Treg fraction that can
change its lineage toward Th17.(28,29) CD161 is a
lectin-like receptor expressed on human NK cells and
T lymphocytes.(41) We have previously demonstrated
that CD161pos T cells in the human liver include both
Th17 and Tc17 cells(42,43) and that these cells are
implicated not only in liver injury but also in the path-
ogenesis of autoimmune Crohn’s disease.(44) LLT1, a
ligand for CD161,(45) is present on antigen-presenting
cells, germinal center B cells, and Kupffer cells.(46,47)
Interactions between CD161 on NK cells and LLT1
on target cells inhibit NK cell-mediated cytotoxicity
and cytokine production.(46-49) We observed signiﬁ-
cantly higher CD161 expression on both NK cells and
Tregs in treatment-naive AIH that declined after ther-
apy and demonstrated that LLT1 is expressed on liver-
inﬁltrating monocytes, B cells, and neutrophils. Thus,
CD161 could be activated by ligand-bearing cells in
the inﬂamed liver to down-regulate effector responses;
but if insufﬁcient ligand is present, this feedback could
be overwhelmed.
We noted that patients who did not respond to
immunosuppressive therapy had a reduced exhausted
T-cell phenotype with lower PD1 expression, which
agrees with a lack of control over effector cells in these
patients with therapy. The B cell frequency was ele-
vated in 20% (5/25 cases) of treatment-naive patients,
and this group might be one that would respond to
anti-B cell therapy, such as rituximab.(39,50)
Our study has its limitations. As only small volumes
of blood (5-10 mL) were supplied by each participat-
ing hospital, the full volume was taken to isolate the
peripheral blood mononuclear cells for immune phe-
notyping; count data on each subset in the whole blood
were not collected. CD45 selection and dead cell
exclusion were not included in the phenotyping panel.
This decision was taken in the study design in order to
maximize the depth of immune subset phenotyping
with the small volume of sample available and access to
only nine color instruments; it was also based on
knowledge that CD45 frequencies of >99% and dead
cell frequencies of 1%-3% are consistently observed
with peripheral blood samples processed under the
same conditions and are seen to have negligible impact
on the frequencies of the populations of interest in the
study (Supporting Figs. S9 and S10; Supporting
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FIG. 7. Diagrammatic illustration of the immune cell composition changes occurring in treatment-naive AIH with 4 months cortico-
steroid therapy. Regulatory T cells in the peripheral blood of patients with treatment-naive acute AIH are predominantly effector
memory in phenotype (CD45RAnegCCR7neg) and express functional proteins CD39, CTLA-4, and FOXP3. They also express the
liver-homing receptor CXCR3 and exhaustion marker PD1. B cells and monocytes in inﬂamed AIH livers express the CD161 ligand
LLT1, and CD161 expression by both NK cells and Tregs is elevated before therapy in patients with acute AIH. CXCL-10 secreted
by inﬂamed hepatocytes and bile ducts attracts CXCR3-expressing NK cells and Tregs to the site of hepatitis in AIH. Both NK cells
and memory Tregs are expanded signiﬁcantly in the peripheral immune cell composite of patients with acute AIH before the start of
therapy compared to after 4 months on corticosteroid. In contrast, the B cell frequency is signiﬁcantly lower at the treatment-naive
acute stage and recovers with corticosteroid.
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Tables S3 and S4). There were differences in the ste-
roid regimen used by different contributing centers,
and these might have inﬂuenced the magnitude of
phenotypic change observed. However, an increase in
variability would be more reasonable to expect; as such,
the conclusions of disease-relevant phenotypes made in
this study are believed to be sound and relevant. Limi-
tation of sample volume to under 10 mL with the cur-
rent UK-AIH ethics meant that in vitro assays to test
the possibility that a lack of NK cell regulation by
Tregs contributes to AIH pathogenesis could not be
evaluated on patient blood as such analysis required
around 50 mL. Despite these limitations, the study has
identiﬁed interesting and novel phenotypic changes
with therapy in a unique, rare, and poorly understood
cohort, which can now guide the direction of further
studies to address in more detail the pathologic mecha-
nisms underlying AIH pathogenesis and direct
improved and stratiﬁed therapeutic strategies with
reduced side effects.
In conclusion, our study is the ﬁrst to report longitu-
dinal changes in detailed leucocyte subsets in AIH
(Fig. 7). The changes in the balance of NK cells and
Tregs in treatment-naive patients suggest a switch in
the effector/regulatory balance that might be amenable
to therapy. The relevance of the NK cell changes is
supported by the correlation with liver injury early in
disease. Further studies using deep immunophenotyp-
ing with mass cytometry in well-characterized cohorts
of patients are required before immunophenotyping
can be used for treatment stratiﬁcation.
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